The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The expansion includes a larger technical and service team and increased local procurement
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
Subscribe To Our Newsletter & Stay Updated